Aditxt stock jumps in premarket after 36% rally as Jan. 30 vote nears

Aditxt stock jumps in premarket after 36% rally as Jan. 30 vote nears

New York, Jan 21, 2026, 05:40 EST — Premarket

  • Aditxt shares jumped roughly 25% in premarket action, following a 36% gain on Tuesday’s close
  • Traders are eyeing the Jan. 30 shareholder meeting, where votes will cover Nasdaq rules, a potential name change, and a possible reverse split
  • Attention stays on Nasdaq compliance following a December notice linked to stockholders’ equity

Aditxt Inc shares jumped roughly 25% in premarket trading Wednesday, following a 35.6% gain in the prior session. The stock was last seen near $1.47 before the open, up from Tuesday’s close at $1.18. About 35 million shares traded during the regular session. (StockAnalysis)

The recent surge in trading shines a light on a company valued at just around $2 million, where even minor trades can send prices swinging wildly. On top of that, a shareholder vote scheduled for next week and ongoing Nasdaq compliance issues continue to cast a shadow on the stock. (StockAnalysis)

On Dec. 16, Aditxt announced a special meeting set for Jan. 30, giving shareholders a chance to vote on several proposals. These include approvals under Nasdaq Marketplace Rule 5635(d) related to prior preferred stock and warrant financings. Investors will also consider an employee stock purchase plan and a massive increase in the 2021 equity plan’s share pool—from just 3 shares to 350,000. Additionally, there’s a non-binding vote on renaming the company to “bitXbio, Inc.” and a potential reverse stock split ranging anywhere from 1-for-5 up to 1-for-250. (SEC)

Rule 5635(d) acts as one of Nasdaq’s safeguards against discounted stock offerings. Simply put, it may force a company to get shareholder approval before issuing stock—or stock-linked securities—that total 20% or more of outstanding shares at prices below recent market levels.

Aditxt is facing a separate Nasdaq notice concerning its stockholders’ equity, a key balance-sheet figure that subtracts liabilities from assets. In a Dec. 5 filing, the company revealed that Nasdaq flagged its Sept. 30 quarterly report’s equity level as falling short of the exchange’s minimum. Aditxt has until Jan. 15 to present a plan to fix this; Nasdaq may extend the deadline to May 30 if it approves the proposal. (SEC)

Tuesday’s session saw an extraordinary surge in activity for Aditxt. Around 35 million shares changed hands—about 80 times its 20-day average volume of roughly 431,000, according to data from Stock Analysis. (StockAnalysis)

The proxy materials reveal a well-worn strategy for companies aiming to keep their listings: increased leeway to issue stock and the possibility of another reverse split. A reverse stock split combines existing shares into fewer shares, usually to boost the share price, though it leaves the company’s overall value unchanged.

That setup, however, poses risks for current shareholders. Should the proposals pass, Aditxt might issue additional shares linked to preferred stock conversions and warrant exercises, potentially diluting existing stakes. Plus, reverse splits often trigger selling pressure once implemented.

The stock now faces a clear milestone. Investors are focused on the Jan. 30 vote and any new word from Nasdaq on Aditxt’s compliance plan. After that, all eyes will be on whether the company can demonstrate progress before the May 30 deadline outlined in its filing.

Stock Market Today

  • GLN.AX surges 30% pre-market on ASX as overbought signals warn pullback
    January 21, 2026, 8:56 AM EST. Galan Lithium Limited (GLN.AX) surged 30% to A$0.455 in ASX pre-market trading on Jan 22, with volume nearly tripling average daily levels, indicating heavy buying interest. The company's lithium-focused exploration projects benefit from strong sector momentum, yet technical indicators show overbought conditions, warning investors of potential correction. Key metrics like negative earnings and cash flow reflect its early explorer status and caution long-term valuation. Meyka AI assigns a HOLD rating with a B grade, forecasting significant downside over one and three years despite current gains. Traders should watch support at A$0.38 and resistance near A$0.60 amid expected volatility.
Corvus Pharmaceuticals stock whipsaws: CRVS slides after $150 million offering follows eczema data surge
Previous Story

Corvus Pharmaceuticals stock whipsaws: CRVS slides after $150 million offering follows eczema data surge

Lottery.com stock slips premarket after $1.7 million offering and $150 million loan exit
Next Story

Lottery.com stock slips premarket after $1.7 million offering and $150 million loan exit

Go toTop